Article
Immunology
Julien Pothlichet, Annalisa Meola, Florence Bugault, Louise Jeammet, Anne G. Savitt, Berhane Ghebrehiwet, Lhousseine Touqui, Philippe Pouletty, Frederic Fiore, Alain Sauvanet, Jacques Theze
Summary: The impaired CD4 T-cell response and immunodeficiency of HIV-infected patients is partially caused by the interaction between PLA2G1B phospholipase and the HIV gp41 envelope protein, which leads to the formation of abnormal membrane microdomains that trap and inactivate physiological receptors. This study demonstrates that gp41 directly binds to PLA2G1B and increases its enzymatic activity on CD4 T-cell membranes. The 3S sequence of gp41, which binds to the innate sensor gC1qR, plays a critical role in the regulation of PLA2G1B activity. This mechanism may also be involved in other infectious diseases and pancreatic cancer.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Jian Zhang, Hongyan Zhang, Xiuli Ding, Jia Hu, Yongkui Li, Jinxiang Zhang, Hui Wang, Shanshan Qi, Aqing Xie, Jie Shi, Mengxi Xiang, Yawen Bin, Guobin Wang, Lin Wang, Zheng Wang
Summary: This study reveals a previously unappreciated TAM-mediated oncogenic network in hepatocellular carcinoma (HCC), where TAMs induce and maintain high levels of HCC UHRF1 expression, leading to the dysregulation of tumor inhibitory factors KLF6 and miR-520d. Targeting this network may provide a new approach for the treatment of HCC patients.
Article
Oncology
Qing Li, Qing Chao, Yue Liu, Jiayu Fang, Jing Xie, Jing Zhen, Yongqi Ding, Bidong Fu, Yun Ke, Fan Xiao, Honghu Wu, Zhaoxia Huang, Haibin Hao, Da Huang
Summary: The study demonstrates the high expression of ZRANB1 in hepatocellular carcinoma (HCC) and its correlation with poor prognosis. ZRANB1 may promote HCC cell growth and metastasis by regulating LOXL2.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Cell Biology
Jinghe Xie, Tingting Guo, Zhiyong Zhong, Ning Wang, Yan Liang, Weiping Zeng, Shoupei Liu, Qicong Chen, Xianglian Tang, Haibin Wu, Shuai Zhang, Keqiang Ma, Bailin Wang, Yimeng Ou, Weili Gu, Honglin Chen, Yaqi Qiu, Yuyou Duan
Summary: Integrin beta 1 (ITGB1) has emerged as a therapeutic target for HCC treatment, with higher expression found in HCC tissues. ITGB1 was shown to regulate PXN and YWHAZ in HCC cell cycle progression. Inhibition of ITGB1 expression led to downregulation of PXN and YWHAZ and reduced aggressive behavior of HCC tumor cells.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Immunology
Weiwen Zhang, Anna B. Morris, Erica V. Peek, Geeta Karadkhele, Jennifer M. Robertson, Haydn T. Kissick, Christian P. Larsen
Summary: T cells induced by CMV infection can have long-term impact on immune responses, potentially detrimental to transplant patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Yang Yang, Pengwei Ren, Xiaofeng Liu, Xiaoyan Sun, Chunfeng Zhang, Xiaojuan Du, Baocai Xing
Summary: This study found that PPP1R26 is upregulated in hepatocellular carcinoma (HCC) and is significantly associated with metastasis and poor patient survival. PPP1R26 promotes glycolysis by enhancing the splicing of PKM2 and activates epithelial-mesenchymal transition (EMT) by forming a PPP1R26-PKM2-TGIF2 complex, driving the progression of HCC.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Immunology
Xiao-Peng Dai, Feng-Ying Wu, Cheng Cui, Xue-Jiao Liao, Yan-Mei Jiao, Chao Zhang, Jin-Wen Song, Xing Fan, Ji-Yuan Zhang, Qing He, Fu-Sheng Wang
Summary: Platelet-T cell aggregates play a critical role in maintaining inflammation in chronic HIV-1 infection. The formation of platelet-CD4(+) T cell aggregates was increased in treatment-naive HIV-1-infected individuals compared to healthy controls. Higher levels of these aggregates were associated with HIV-1 permissiveness and immune activation during HIV-1 infection.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Hao Shen, Han Yu, Qian-yu Li, Ya-ting Wei, Jing Fu, Hui Dong, Dan Cao, Lin-na Guo, Lei Chen, Yuan Yang, Ying Xu, Meng-chao Wu, Hong-yang Wang, Yao Chen
Summary: Non-alcoholic fatty liver disease (NAFLD) is a prevalent risk factor for hepatocellular carcinoma (HCC). The progression from NAFLD to HCC involves paracrine communication among hepatic cells. Vascular endothelial growth factor A (VEGFA) plays a crucial role in NAFLD and HCC, but its cellular communication in the transition from NAFLD to HCC is still unclear.
ACTA PHARMACOLOGICA SINICA
(2022)
Article
Biochemistry & Molecular Biology
Kaibin Shi, Handong Li, Ting Chang, Wenyan He, Ying Kong, Caiyun Qi, Ran Li, Huachen Huang, Zhibao Zhu, Pei Zheng, Zhe Ruan, Jie Zhou, Fu-Dong Shi, Qiang Liu
Summary: The study reveals that bone marrow hematopoietic stem and progenitor cells (HSPCs) in multiple sclerosis patients are skewed towards myeloid lineage, while T cells undergo clonal expansion. Animal model research demonstrates a significant bone marrow myelopoiesis, offering a new avenue for treating MS.
Review
Cell Biology
May G. Akl, Scott B. Widenmaier
Summary: Hepatocellular carcinoma (HCC) is a major public health concern promoted by obesity-related liver complications. The transition from steatosis to steatohepatitis and from steatohepatitis to HCC involves complex interactions between metabolic and immune pathways. Understanding these immunometabolic changes associated with HCC in obesity may contribute to the development of targeted therapies.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Article
Cell Biology
Goutham Venkata Naga Davuluri, Chien-Chin Chen, Yen-Cheng Chiu, Hung-Wen Tsai, Hung-Chih Chiu, Yuh-Ling Chen, Pei-Jane Tsai, Wan-Ting Kuo, Nina Tsao, Yee-Shin Lin, Chih-Peng Chang
Summary: Galectin-1 (Gal-1), a secretory lectin associated with hepatocellular carcinoma (HCC), can be actively secreted by tumor-associated macrophages (TAMs) in response to stimuli of HCC cells, leading to increased systemic levels of Gal-1 and HCC tumor growth in mice. Autophagy-regulated Gal-1 secretion from TAMs correlates with poor overall survival and progression-free survival rates of HCC patients, highlighting the pathological role of TAM-produced Gal-1 in HCC progression.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Immunology
Qian Zhang, Lanlan Yang, Siqi Liu, Mengyao Zhang, Zhenjing Jin
Summary: This study found that in HBV-related HCC patients, IL-35 may attenuate the activity of Th9 cells, resulting in the suppression of cytotoxicity of CD8(+) T cells.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Guixi Zheng, Hakim Bouamar, Matyas Cserhati, Carla R. Zeballos, Isha Mehta, Habil Zare, Larry Broome, Ruolei Hu, Zhao Lai, Yidong Chen, Francis E. Sharkey, Meenakshi Rani, Glenn A. Halff, Francisco G. Cigarroa, Lu-Zhe Sun
Summary: The study found that ITGA6 is upregulated in HCC tumors and has a malignant promoting role in HCC cells through integrin alpha 6 beta 4 complex. Thus, integrin alpha 6 beta 4 may be a therapeutic target for treating HCC patients.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Zhixiong Li, Yongchun Wang, Rui Xing, Huilan Zeng, Xing-Juan Yu, Yao-jun Zhang, Jing Xu, Limin Zheng
Summary: The reprogramming of cholesterol metabolism in monocytes in the tumor microenvironment promotes hepatocellular carcinoma progression. Selectively modulating cholesterol metabolism in specific cell subsets may be an effective strategy for cancer therapy.
CANCER IMMUNOLOGY RESEARCH
(2023)
Article
Gastroenterology & Hepatology
Tongxin Wang, Kai Chen, Weilei Yao, Ruilong Zheng, Qiongyu He, Jun Xia, Juan Li, Yafei Shao, Li Zhang, Lu Huang, Longshan Qin, Mingming Xu, Zheng Zhang, Dingyu Pan, Zhen Li, Feiruo Huang
Summary: The study found that hyperacetylation of LDHB in NAFL and NASH livers leads to lactate accumulation, exacerbating lipid deposition and inflammatory responses. Inhibition of PCAF and the generation of an acetylation-deficient mutant of LDHB can ameliorate NASH, suggesting a potential therapeutic target for the disease.
JOURNAL OF HEPATOLOGY
(2021)
